Literature DB >> 22992839

Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.

Elena Beam1, Raymund R Razonable.   

Abstract

Cytomegalovirus (CMV) is one of the most important pathogens that infect solid organ transplant recipients. CMV is associated with increased morbidity and mortality in this population as a result of its numerous direct and indirect effects. Prevention strategies consist of preemptive therapy and antiviral prophylaxis, and the choice of which preventive approach to implement should be guided by advantages and drawbacks related to the population being managed. There are differences in the approaches to the laboratory diagnosis and treatment of CMV infection and disease depending on assay availability, clinical presentation, disease severity, and specific transplant populations. In this article, the authors aim to summarize recent publications and updates in the epidemiology, diagnosis, prevention, and treatment of CMV infection in solid organ transplant recipients during the past year, including a brief review of future directions in the field.

Entities:  

Year:  2012        PMID: 22992839     DOI: 10.1007/s11908-012-0292-2

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  39 in total

1.  Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.

Authors:  Carlos Paya; Atul Humar; Ed Dominguez; Kenneth Washburn; Emily Blumberg; Barbara Alexander; Richard Freeman; Nigel Heaton; Mark D Pescovitz
Journal:  Am J Transplant       Date:  2004-04       Impact factor: 8.086

2.  The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response.

Authors:  Luiz F Lisboa; Anders Asberg; Deepali Kumar; Xiaoli Pang; Anders Hartmann; Jutta K Preiksaitis; Mark D Pescovitz; Halvor Rollag; Alan G Jardine; Atul Humar
Journal:  Transplantation       Date:  2011-01-27       Impact factor: 4.939

3.  The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients.

Authors:  A Humar; Y Lebranchu; F Vincenti; E A Blumberg; J D Punch; A P Limaye; D Abramowicz; A G Jardine; A T Voulgari; J Ives; I A Hauser; P Peeters
Journal:  Am J Transplant       Date:  2010-03-26       Impact factor: 8.086

4.  First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246.

Authors:  D R Kaul; S Stoelben; E Cober; T Ojo; E Sandusky; P Lischka; H Zimmermann; H Rubsamen-Schaeff
Journal:  Am J Transplant       Date:  2011-05       Impact factor: 8.086

5.  Comparison of real-time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants.

Authors:  Simona Marchetti; Rosaria Santangelo; Stefania Manzara; Sara D'onghia; Giovanni Fadda; Paola Cattani
Journal:  New Microbiol       Date:  2011-04-30       Impact factor: 2.479

6.  Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients.

Authors:  W Bosch; M G Heckman; N N Diehl; J A Shalev; S Pungpapong; W C Hellinger
Journal:  Am J Transplant       Date:  2011-08-09       Impact factor: 8.086

7.  Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.

Authors:  Hans-Arne Myhre; Dagny Haug Dorenberg; Knut Ivan Kristiansen; Halvor Rollag; Torbjørn Leivestad; Anders Asberg; Anders Hartmann
Journal:  Transplantation       Date:  2011-07-27       Impact factor: 4.939

8.  Epidemiology of cytomegalovirus infection after pancreas transplantation.

Authors:  Ajay K Parsaik; Tajinder Bhalla; Ming Dong; Nassir Rostambeigi; Ross A Dierkhising; Patrick Dean; Roshini Abraham; Mikel Prieto; Walter K Kremers; Raymund R Razonable; Yogish C Kudva
Journal:  Transplantation       Date:  2011-11-15       Impact factor: 4.939

Review 9.  Antiviral drug resistance of human cytomegalovirus.

Authors:  Nell S Lurain; Sunwen Chou
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

10.  Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors.

Authors:  E Cordero; C Casasola; R Ecarma; R Danguilan
Journal:  Transplant Proc       Date:  2012-04       Impact factor: 1.066

View more
  35 in total

Review 1.  Cytomegalovirus infection in liver transplant recipients: updates on clinical management.

Authors:  Jasmine Riviere Marcelin; Elena Beam; Raymund R Razonable
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Human Cytomegalovirus Infection in Women With Preexisting Immunity: Sources of Infection and Mechanisms of Infection in the Presence of Antiviral Immunity.

Authors:  William J Britt
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

3.  Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment.

Authors:  Dirk Kropeit; Jürgen Scheuenpflug; Katharina Erb-Zohar; Atef Halabi; Hans-Peter Stobernack; Ellen G J Hulskotte; Arne van Schanke; Holger Zimmermann; Helga Rübsamen-Schaeff
Journal:  Br J Clin Pharmacol       Date:  2017-05-05       Impact factor: 4.335

4.  KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.

Authors:  Krista L Lentine; Bertram L Kasiske; Andrew S Levey; Patricia L Adams; Josefina Alberú; Mohamed A Bakr; Lorenzo Gallon; Catherine A Garvey; Sandeep Guleria; Philip Kam-Tao Li; Dorry L Segev; Sandra J Taler; Kazunari Tanabe; Linda Wright; Martin G Zeier; Michael Cheung; Amit X Garg
Journal:  Transplantation       Date:  2017-08       Impact factor: 4.939

5.  Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.

Authors:  Dirk Kropeit; David McCormick; Katharina Erb-Zohar; Valentin S Moiseev; Zhanna D Kobalava; Hans-Peter Stobernack; Holger Zimmermann; Helga Rübsamen-Schaeff
Journal:  Br J Clin Pharmacol       Date:  2017-08-27       Impact factor: 4.335

Review 6.  Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation.

Authors:  Raymund R Razonable; Randall T Hayden
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

7.  Fully automated quantification of cytomegalovirus (CMV) in whole blood with the new sensitive Abbott RealTime CMV assay in the era of the CMV international standard.

Authors:  Nathalie Schnepf; Catherine Scieux; Matthieu Resche-Riggon; Linda Feghoul; Alienor Xhaard; Sébastien Gallien; Jean-Michel Molina; Gérard Socié; Denis Viglietti; François Simon; Marie-Christine Mazeron; Jérôme Legoff
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948

8.  Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.

Authors:  Daniel C Freed; Qi Tang; Aimin Tang; Fengsheng Li; Xi He; Zhao Huang; Weixu Meng; Lin Xia; Adam C Finnefrock; Eberhard Durr; Amy S Espeseth; Danilo R Casimiro; Ningyan Zhang; John W Shiver; Dai Wang; Zhiqiang An; Tong-Ming Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

9.  Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients: a Focus on Prevention.

Authors:  Karen C Tsai; Lara A Danziger-Isakov; David B Banach
Journal:  Curr Infect Dis Rep       Date:  2016-01       Impact factor: 3.725

10.  Perivascular stromal cells as a potential reservoir of human cytomegalovirus.

Authors:  M A Soland; L R Keyes; R Bayne; J Moon; C D Porada; S St Jeor; G Almeida-Porada
Journal:  Am J Transplant       Date:  2014-03-04       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.